Is ARYx Therapeutics, Inc. (ARYX) a Buy, Sell, or Hold?
OTC : ARYX
ARYx Therapeutics, Inc.
$0.0005 USD
$0 (0.0%)
- Volume
- 2K
- Average Volume
- 1.84K
- Market Capitalization
- $16.73K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.01
Company Overview
OTC
Paul Goddard
Drug Manufacturers - Specialty & Generic
Healthcare
ARYX
56
US
USD
Liquidity Metrics
-4.05
1.01
1.01
0.85
0.00
Sales & Valuation
-$
0.00
0.00
0.00
-1.28
Profitability
-$1.21
-$33.17M
0.00%
0.00%
-270.76%
-267.35%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Poll Results
No votes yet today — be the first to share your view!
About ARYx Therapeutics, Inc. (OTC:ARYX) Stock
Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc. is dedicated to discovering and advancing innovative treatments, primarily focusing on widespread, chronic conditions addressable with oral medications. The company utilizes its unique RetroMetabolic Drug Design technology to engineer distinctive molecular compounds that maintain the therapeutic effectiveness of their original counterparts. Its clinical development portfolio includes several promising candidates: Tecarfarin (ATI-5923): An oral anticoagulant currently in Phase III clinical trials, aimed at preventing hazardous blood clots in at-risk patients. Budiodarone (ATI-2042): An oral antiarrhythmic agent undergoing Phase IIb development for managing atrial fibrillation, a form of irregular heart rhythm. AT ... I-7505: An oral prokinetic agent in Phase IIb clinical development, targeting various gastrointestinal issues such as chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease. ATI-9242: An antipsychotic agent progressing through Phase I clinical trials for the treatment of schizophrenia and other psychiatric conditions. Additionally, ARYx Therapeutics is conducting early-stage research on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal ailments.
Frequently Asked Questions
-
What is the current ARYx Therapeutics, Inc. (ARYX) stock price?
-
ARYx Therapeutics, Inc.(OTC:ARYX) stock price is $0.0005 in the last trading session. During the trading session, ARYX stock reached the peak price of $0.0005 while $0.000001 was the lowest point it dropped to. The percentage change in ARYX stock occurred in the recent session was 0.0% while the dollar amount for the price change in ARYX stock was $0.
-
ARYX's industry and sector of operation?
-
The OTC listed ARYX is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of ARYX?
-
|
|
|
|
| -
How many employees does ARYX have?
-
Number of ARYX employees currently stands at 56. ARYX operates from 6300 Dumbarton Circle, Fremont, CA 94555, US.
-
Link for ARYX official website?
-
Official Website of ARYX is: https://www.aryx.com
-
How do I contact ARYX?
-
ARYX could be contacted at phone #510 585 2200 and can also be accessed through its website. ARYX operates from 6300 Dumbarton Circle, Fremont, CA 94555, US.
-
How many shares of ARYX are traded daily?
-
The average number of ARYX shares traded daily for last 3 months was 1.84K.
-
What is the market cap of ARYX currently?
-
The market value of ARYX currently stands at $16.73K with its latest stock price at $0.0005